Page 96 - Haematologica June

998
S. Bertoli et al.
TOUCAN and La Ligue Contre le Cancer. EG is supported by a postdoctoral grant from La Fondation de France.
The authors would like to thank the data management unit of Toulouse University Hospital for its support enabling e-CRF. We thank Dr. Véronique De Mas for the management of the
Biobank BRC-HIMIP (Biological Resources Centres-INSERM Midi-Pyrénées “Cytothèque des Hémopathies Malignes”). We also thank all the members of the Gaël Adolescent Espoir Leucémie (GAEL). Finally, we are indebted to Dr. Mary Selak for the critical reading of the manuscript.
References
1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
2. Rollig C, Ehninger G. How I treat hyper- leukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246-3252.
3. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106.
4. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27(16):2668- 2676.
5. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777-2782.
6. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell acti- vation by myeloblasts: molecular mecha- nisms of leukostasis and leukemic cell dis- semination. Blood. 2001;97(7):2121-2129.
7. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987;70(4):1218-1221.
8. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2-3):69-75.
9. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
10. Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013;121(14):2618-2626.
11. Pigneux A, Harousseau JL, Witz F, et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly
patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol. 2010;28(18):3028-3034.
12. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommenda- tions from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
13. Chabrol A, Cuzin L, Huguet F, et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during build- ing work in patients with acute leukemia. Haematologica. 2010;95(6):996-1003.
leukemia is enriched for leukemia stem cell genes. Leuk Lymphoma. 2015;56(4):1126- 1128.
21. Simon L, Lavallee VP, Bordeleau ME, et al. Chemogenomic landscape of RUNX1- mutated AML reveals importance of RUNX1 allele dosage in genetics and gluco- corticoid sensitivity. Clin Cancer Res. 2017;23(22):6969-6981.
22. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res. 1997;21(1):45-50.
23. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-
14. Cheson BD, Bennett JM, Kopecky KJ, et al.
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria,
Treatment Outcomes, and Reporting 134.
Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
15. Griessinger E, Anjos-Afonso F, Vargaftig J, et al. Frequency and dynamics of leukemia- Initiating cells during short-term ex vivo culture informs outcomes in acute myeloid leukemia patients. Cancer Res. 2016;76(8): 2082-2086.
16. Griessinger E, Anjos-Afonso F, Pizzitola I, et al. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med. 2014;3(4):520-529.
17. Kurata M, Rathe SK, Bailey NJ, et al. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep. 2016;6:36199.
18. Malani D, Murumagi A, Yadav B, et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017;31(5):1187-1195.
19. Farge T, Saland E, de Toni F, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716- 735.
20. Hackl H, Steinleitner K, Lind K, et al. A gene expression profile associated with relapse of cytogenetically normal acute myeloid
24. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
25. Hicsonmez G. The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apop- tosis and in stimulating myelopoiesis. Leuk Res. 2006;30(1):60-68.
26. Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130(15):1693- 1698.
27. Rosen JM, Jordan CT. The increasing com- plexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670-1673.
28. Volk A, Li J, Xin J, et al. Co-inhibition of NF- kappaB and JNK is synergistic in TNF- expressing human AML. J Exp Med. 2014;211(6):1093-1108.
29. Schepers K, Campbell TB, Passegue E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16(3):254-267.
30. Korn C, Mendez-Ferrer S. Myeloid malig- nancies and the microenvironment. Blood. 2017;129(7):811-822.
31. Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a sys- tematic review and meta-analysis. Leuk Res. 2014;38(4):460-468.
haematologica | 2018; 103(6)